The FDA has expanded its approval of a CRISPR-based therapy, known as Casgevy, developed by Vertex and CRISPR Therapeutics, to treat beta thalassemia, an inherited blood disorder. This therapy, previously cleared for sickle cell disease, is the first drug in the United States to use the revolutionary gene-editing tool called CRISPR-Cas9 for a second rare blood disorder. The approval marks a significant milestone in the use of gene editing technology to address genetic diseases.
A therapy based on CRISPR gene-editing technology that the FDA approved in December for sickle cell disease can be used for a second inherited blood disorder. https://t.co/RIjHFjtKM6
Casgevy is the second genetic medicine to secure FDA approval for beta thalassemia. https://t.co/4qxYkzW5ZX
FDA expands use of newly approved CRISPR therapy https://t.co/pU3s7uJdLE
FDA has approved one on but two CRISPR based gene therapies. Starting with rare diseases, as readers of @razibkhan know to expect You love to see it! 🧬 https://t.co/wsODLN92V5 https://t.co/iX3uqnnsaI
In Another Win for CRISPR, FDA Approves Casgevy for Beta Thalassemia. Learn more: https://t.co/CH4rpSYFT9 https://t.co/EI7vkidJWS
The FDA approved a CRISPR-based medicine, Casgevy, to treat beta thalassemia, an inherited blood disorder. https://t.co/cZ7dvqbZbM
A therapy based on CRISPR gene-editing technology that the FDA approved in December for sickle cell disease can be used for a second inherited blood disorder. https://t.co/InkxPaK5UF
FDA Approved a new CRISPR gene-editing treatment for transfusion-dependent beta thalassemia. This one is from Vertex and CRISPR Therapeutics I have been telling you, CRISPR Therapeutics $CRSP is the way https://t.co/mBS5a9wDSY
FDA Approved a new CRISPR gene-editing treatment for thalassemia. I have been telling you, CRISPR Therapeutics $CRSP is the way https://t.co/I9t176kzyl
Gene-editing treatment from Vertex and CRISPR cleared for second rare blood disorder https://t.co/cAHVOTmrhR
Casgevy, the first drug approved in the United States to use the revolutionary gene-editing tool called CRISPR-Cas9, was cleared by regulators on Tuesday to treat a second rare blood disorder. https://t.co/TfJrd1VxLe
FDA Approves New CRISPR Gene-Editing Treatment https://t.co/3hiwbE7PGP https://t.co/gTZxrj4eU4
US FDA approves Vertex/CRISPR gene therapy for an inherited blood disorder https://t.co/qavmFmkRip https://t.co/2Xtm4HkExf
The FDA approved a CRISPR-based medicine to treat beta thalassemia, an inherited blood disorder. It’s the same potentially curative therapy cleared by the FDA to treat sickle cell disease. https://t.co/fj54UIOWlc
FDA expands approval of CRISPR-based medicine to treat beta thalassemia https://t.co/hoM2HpuZpJ via @adamfeuerstein for @statnews
The FDA has approved a gene editing therapy from Vertex and Crispr to treat another illness https://t.co/UXrfr6qQ1B
FDA expands approval of CRISPR-based therapy to treat beta thalassemia https://t.co/Yfoifo7iCa
Breaking: FDA approves Vertex-CRISPR gene editing therapy for beta-thalassemia - https://t.co/trtFHhPslm